Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-week regimen in a real-world setting.
Zarębska-Michaluk D, Piekarska A, Jaroszewicz J, Klapaczyński J, Sitko M, Tudrujek-Zdunek M, Tomasiewicz K, Belica-Wdowik T, Pabjan P, Lorenc B, Czauż-Andrzejuk A, Tronina O, Krygier R, Dobracki W, Buczyńska I, Simon KA, Dybowska D, Halota W, Pawłowska M, Citko J, Laurans Ł, Mazur W, Janczewska E, Socha Ł, Deroń Z, Berak H, Flisiak R.
Zarębska-Michaluk D, et al. Among authors: jaroszewicz j.
Arch Med Sci. 2019 Jul 11;18(6):1460-1466. doi: 10.5114/aoms.2019.86569. eCollection 2022.
Arch Med Sci. 2019.
PMID: 36457986
Free PMC article.